A phase 3 BASIS analysis examined the use of factor replacement therapy for breakthrough bleeds and the perioperative management of minor and dental procedures among patients receiving marstacimab...
In a post hoc analysis of the phase 3 HELIOS-B trial, vutrisiran reduced worsening of left atrial strain at 30 months among patients with transthyretin amyloidosis with cardiomyopathy.
Canadian researchers assessed whether exposure to wildfire-related fine particulate matter was associated with ED visits for migraine and other headaches.
No HIV acquisitions occurred among 315 cisgender and transgender women receiving long-acting cabotegravir PrEP in the real-world US OPERA Cohort, despite mostly short injection delays.
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
August 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a...
A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
In 2 phase 3 randomized, placebo-controlled trials of adults and adolescents with nonsegmental vitiligo, once-daily upadacitinib 15 mg significantly improved facial and total-body repigmentation at 48...
